|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
April 2009FeaturesCover Story Biologic Vaccines: A Panacea for Infectious Diseases?The threat of new disease pandemics has spurred the development of biologic vaccines, which promise tremendous improvements in global and local health. Several lend themselves to the prevention or treatment of chronic diseases. But the uncertainties of whom to vaccinate raise the question of whether the health care system can make these promising products viable. Controlling the Cost of Care through Clinical PathwaysA look at how two health plans have integrated physician-developed clinical pathways into their networks. The Future of Biologics, Part I: Opportunity, Resources, and Affordability: Multistakeholder PerspectivesOn two occasions last year, the Jefferson School of Population Health convened a National Advisory Board of scientists and opinion leaders from key stakeholder groups at a high-level forum to explore different perspectives and to discuss improving access for patients who require treatment with biologic drugs. The following is the first of two articles documenting these discussions. The second article will appear in a subsequent issue of Biotechnology Healthcare. Payers Tightening Management of Specialty TherapiesContinued market growth among specialty therapies has attracted the attention of big pharma and investors. Many payers, however, believe the industry has reached a tipping point, where greater management focus — and tougher decisions — are needed. DepartmentsOpeners The Loch Ness Vaccine
Michael D. Dalzell Editorial Playing GamesWhat Everquest teaches us about leadership. Personalized Medicine DTC Advertising: Where Do Genetic Tests Fit?Is there a place for genetic tests in DTC ads? Drug Track Research, Conferences, and FDA Actions
Schuyler Matthews Specialty Pharmacy Cutting Back Expenses Through Carve-OutsThe crumbling economic environment may be an important catalyst for the heightened interest among employers in carving out specialty drugs.
Employer to Employer What’s Learned When the Health Plan Is the EmployerSizing up a health plan’s health plan. Biotechnology Healthcare’s 2008 Editorial IndexTrends: Consumer-Directed Plans More Employees Turning to High-Deductible Health Plans |
|||||